Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 12/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CALML3 | P27482 | 5/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411105 | 0.91 | CALML3 (0.51) | MAOAMAOBCYP2C19CYP2C9CALML3 | |
| SCHEMBL412833 | 0.90 | MAOA (0.36) | MAOAMAOBCYP2C19CYP2C9CALML3 | |
| SCHEMBL412640 | 0.89 | TDO2 (0.43) | MAOAMAOBCYP2C19CYP2C9CALML3 | |
| SCHEMBL411600 | 0.88 | F10 (0.44) | MAOAMAOBF10 | |
| SCHEMBL411051 | 0.88 | MAOA (0.52) | MAOAMAOBCYP2C19CYP2C9CALML3 | |
| SCHEMBL412789 | 0.88 | F10 (0.42) | MAOAMAOBCYP2C19CYP2C9CALML3 | |
| SCHEMBL411607 | 0.87 | CYP2C19 (0.41) | MAOAMAOBCYP2C19CYP2C9CALML3 | |
| SCHEMBL411601 | 0.87 | MAOA (0.40) | MAOAMAOBCYP2C19CYP2C9CALML3 | |
| SCHEMBL412190 | 0.86 | CYP2C19 (0.39) | MAOAMAOBCYP2C19CYP2C9CALML3 | |
| SCHEMBL412082 | 0.84 | MAOA (0.39) | MAOAMAOBCYP2C19CYP2C9CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | US | disclosed |
| WO-2012033952-A1 | 3 - PHENYL- 2 -OXO- 1, 3 -OXAZOLIDINES FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (KY) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065170-A1 | Antimicrobial Cyclocarbonyl Heterocyclic Compounds For Treatment Of Bacterial Infections | NISCH, SI, VIP | MAOA 853/4885MAOB 427/4885CYP2C19 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.